drugset
drugset / Trial / NCT07106671

A Phase II Study of Siltuximab for CRS/ICANs After CAR-T in Multiple Myeloma

NCT07106671 ↗

Phase 2 Recruiting 20 enrolled Institute of Hematology & Blood Diseases Hospital, China
NaSingle-groupOpen-labelTreatment

Summary

This is a prospective Phase II study evaluating Siltuximab for CRS and ICANS after CAR-T infusion in multiple myeloma patients.

Timeline

Start
2025-08-10
Primary completion
2026-08-01
Completion
2027-08-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Siltuximab Monoclonal antibody 11 mg/kg —

Indications

cytokine release syndrome plasma cell myeloma